Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126668531 | 12666853 | 1 | I | 2011 | 20160815 | 20160819 | 20160819 | EXP | BR-009507513-1608BRA008859 | MERCK | 43.00 | YR | M | Y | 67.00000 | KG | 20160819 | CN | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126668531 | 12666853 | 1 | PS | LOSARTAN POTASSIUM. | LOSARTAN POTASSIUM | 1 | Oral | 50 MG, Q12H | 20386 | 50 | MG | TABLET | Q12H | ||||||
| 126668531 | 12666853 | 2 | C | INDAPEN | INDAPAMIDE | 1 | Oral | 1.5 MG, QD | 0 | 1.5 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126668531 | 12666853 | 1 | Hypertension |
| 126668531 | 12666853 | 2 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126668531 | 12666853 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126668531 | 12666853 | Diabetes mellitus | |
| 126668531 | 12666853 | Hypercholesterolaemia | |
| 126668531 | 12666853 | Papilloma viral infection | |
| 126668531 | 12666853 | Thyroid disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126668531 | 12666853 | 2 | 201508 | 0 |